Patient Search
 |
 |
|
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
A Randomized Phase II Study of Sotorasib versus Continued Consolidation Durvalumab in Patients with KRAS G12C Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) with Persistent ctDNA Defined Minimal Residual Disease
Not Available
II
Whitaker, Ryan
NCT06333678
VICC-ITTHO23274
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Not Available
III
Luckenbaugh, Amy
NCT06111235
VICC-DDURO24101
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma
Not Available
II/III
Johnson, Douglas
NCT06581406
VICC-DTMEL24090
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Not Available
II
Esbenshade, Adam
NCT06368817
COGACNS2321
An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors
Not Available
I/II
Eng, Cathy
NCT06526819
VICC-DTPHI23348
A Randomized Phase III of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Not Available
III
Davis, Elizabeth
NCT06422806
VICC-NTSAR24139
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Not Available
I
Rosenthal, Eben
VICCHNP24602
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
Not Available
III
Choe, Jennifer
NCT06475989
ECOGHNEA3231
ALTE2131 Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer an NCORP Phase 3 Study
Not Available
III
Davis, Elizabeth
NCT06513962
COGALTE2131
